Also worth noting that this was a Phase II drug - not a...

Also worth noting that this was a Phase II drug - not a discovery level peptide that has yet to be proven to have drug-like characteristics, yet alone efficacy in a disease model. The one thing PYC have failed consistently to do is take anything through a proper pre-clinical program, yet alone get into a human. This is the major reason big pharma won't buy them out or do significant deals, as they are so far from being market-ready (8 - 10 years) that there is too much risk, and therefore little value. Tony and Wayne can tyre-pump all they like, but this is reality. Terrible waste of a potentially great platform.